Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(7):495; doi:10.1093/jnci/96.7.495-b
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Intermediate End Point for Prostate Cancer Mortality

Whether the prostate-specific antigen (PSA) response to salvage hormonal therapy can act as an intermediate end point for prostate cancer–specific mortality (PCSM) remains unclear. D’Amico et al. (p. 509) evaluated whether PSA response—the ratio of the rate of PSA change after salvage hormonal therapy to the rate of PSA change before salvage therapy—is associated with PCSM by using data from a single institution and two pooled multi-institutional databases. They found that PSA response was statistically significantly associated with time to PCSM following salvage hormonal therapy; however, its constituents (i.e., . . . [Full Text of this Article]

ER Status of Primary and Contralateral Breast Cancers

Decreasing Anxiety After Abnormal Mammograms

Caloric Restriction and Breast Cancer Risk

Aspirin Use and Pancreatic Cancer Mortality

Plasma C-Peptide and Risk of Colorectal Cancer